upadacitinib
abbvie
['select-axis', 'select,axis,2', '#0414', 'upadacitinib', ' upa ']
efficacy and safety of upadacitinib from select-axis 2, post hoc analysis in pts with bdmard-inadequate response in as: upa demonstrated efficacy vs pbo at wk 14 across all subgroups of pts with bdmard-ir as ae rates with upa vs pbo abst #0414 #acr2022 
The Division of Rheumatology is proud to serve our patients with rheumatic, auto-immune, and inflammatory disease.